When is the ideal time for the test?

The ideal time for testing is at 10 weeks of pregnancy, as this is when a higher percentage of the baby's DNA is present in the mother's blood.


Less invasive tests

mean less risk for both the mother and the fetus.



Results are available within 5 to 7 working days

Compared to traditional
biochemical screening tests, NIPTiva
test provides a significantly more comprehensive approach.

Information for doctors

Choosing the right NIPTiva test is important for your patients. Although there are various NIPT methods available, next-generation sequencing (NGS) is the gold standard for non-invasive prenatal testing. VeriSek NIPTiva from Smart Genetics is a non-invasive prenatal test that can help doctors accurately detect fetal chromosomal abnormalities as early as 10 weeks of pregnancy. NIPTiva based on whole-genome sequencing has lower rates of inconclusive results compared to other technologies. Inconclusive results can lead to increased patient and physician anxiety and potentially lead to an increased number of invasive follow-up procedures to obtain information. Smart Genetics VeriSek NIPTiva v2 uses cell-free DNA (cfDNA) analysis for screening common chromosomal abnormalities such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome), as well as abnormalities in sex chromosomes.

VeriSek NIPTiva v2 allows us to sequence the baby's entire genome using a complex and highly optimized bioinformatics algorithm. The possibility of human error in performing non-invasive prenatal testing is minimized, in compliance with Illumina company regulations necessary for laboratory certification, and the entire process is automated. Unlike invasive procedures such as amniocentesis and chorionic villus sampling (CVS), which carry the risk of miscarriage and are usually performed in the second trimester, VeriSek NIPTiva v2 from Smart Genetics is a low-risk, non-invasive test that can be performed much earlier in pregnancy. The test is performed by simply drawing blood from the mother, which is then sent to our laboratory for analysis. VeriSek NIPTiva v2 from Smart Genetics has high sensitivity and specificity for detecting common chromosomal abnormalities, with a false positive rate of less than 1%. The test also has a high positive predictive value, meaning a positive result indicates the presence of a chromosomal abnormality. VeriSek NIPTiva v2 from Smart Genetics is an important tool for doctors in managing high-risk pregnancies and can provide valuable information to help care for patients and make decisions. However, it is important to have a plan for counseling and follow-up testing in the case of an abnormal result.

Take a prenatal test today